News | June 16, 2008

Angiotech Launches Quill SRS MONODERM for Wound Closure

June 17, 2008 - Angiotech Pharmaceuticals Inc. recently launched marketing of its Quill SRS MONODERM for superficial wound closure.

The product will be available immediately for distribution and sale in the U.S. and Europe.

Quill SRS MONODERM, which is made from a rapidly resorbing polymer, is intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate.

The company said MONODERM is intended primarily for skin closure and will complement its Quill SRS product, which targets deeper layers of wound closure.

Angiotech Pharmaceuticals Inc. is a global specialty pharmaceutical and medical device company that develops and markets treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.

For more information: www.angiotech.com

Related Content

nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
News | Hemostasis Management| January 06, 2016
The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries...
Overlay Init